Developer docs
API playgroundTry for free, no card

Search company profiles

Kobiolabs

Full company profile

uuid0002ihx

Namestring
Kobiolabs
Legal namestring
(주)고바이오랩
Websiteurl
kobiolabs.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

KoBioLabs (고바이오랩) is a South Korea-based, KOSDAQ-listed (ticker 348150) clinical-stage biopharmaceutical company developing Live Biotherapeutic Products (LBPs) from microbiome science for immune, metabolic, neurological, and gastrointestinal diseases. The company operates two integrated discovery platforms — Smartiome®, an AI-based multi-omics analysis platform paired with a microbial strain library of over 8,000 isolates, and Smartiome® 2.0, which adds biofoundry and digital-bio capabilities — together with a proprietary Microbe-Based Drug Delivery System (mDDS) that uses engineered gut microbes to produce therapeutic substances in vivo. Its clinical pipeline spans KBL697 (psoriasis, Phase II complete), KBL693 (asthma, Phase I complete with US FDA IND pending), KBLP-004 (obesity consortium), KBLP-005 (immuno-oncology), KBLP-006 (IBD), KBLP-010 (autism spectrum disorder), KBL409 (chronic kidney disease), and KBL983 (Akkermansia muciniphila for obesity, US-patent protected).

The company's business model is a license-out and research collaboration model rather than direct product sales. Revenue is generated through upfront payments, development and regulatory milestones, and royalties on net sales from global pharmaceutical partners, exemplified by the March 2026 Celltrion license for three intestinal-disease candidates valued at up to 205.2 billion KRW ($136.8 million) — the largest agreement in company history and equal to 417% of 2025 consolidated equity. Additional monetization channels include research collaborations with partners such as Celltrion, a regional China out-license to SPH Sine for KBL697 (2021), and a 2022 joint venture with Emart (Wibiome / 위바이오옴) for health functional foods. Customer segments are exclusively enterprise biopharmaceutical and corporate partners, served via major international biotech conferences (BIO USA, JP Morgan Healthcare Conference, IHMC) rather than direct sales infrastructure.

Short descriptiontext

KoBioLabs is a South Korean, KOSDAQ-listed clinical-stage biopharmaceutical company developing AI-driven, microbiome-based Live Biotherapeutic Products for immune, metabolic, neurological, and gastrointestinal diseases, monetizing its pipeline through out-licensing to global pharmaceutical partners and research collaborations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, live biotherapeutic products, drug discovery platform, multi-omics analysis, synthetic biology
Industry5 codes
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Microbiome Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing
TypeLicensing Royalties
Description

License-out deals with global pharmaceutical companies for drug candidates, including upfront payments, milestone payments tied to clinical progress, regulatory approvals, and commercialization, plus royalties on net sales.

kobiolabs.com
2Research Collaboration
TypeLicensing Royalties
Description

Joint research collaborations with partners like Celltrion for co-development of microbiome-based therapeutics, with shared development costs and potential future revenue sharing.

kobiolabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Smartiome
Description

AI기반 마이크로바이옴 다중오믹스(multi-omics) 분석 기술 및 미생물 라이브러리를 활용한 혁신 신약 개발 플랫폼 기술.

+2 more records
Core offering1 text field

KoBioLabs is a South Korean biopharmaceutical company developing microbiome-based therapeutics (Live Biotherapeutic Products) using its proprietary Smartiome® AI-based multi-omics platform combined with a microbiome library of 8,000+ strains. The company discovers, develops, and out-licenses drug candidates targeting immune, metabolic, neurological, and gastrointestinal diseases to global pharmaceutical partners. Its pipeline includes candidates for psoriasis (KBL697), asthma (KBL693), obesity (KBLP-004, KBL983), inflammatory bowel disease (KBLP-006), autism spectrum disorder (KBLP-010), and chronic kidney disease (KBL409).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • KBL697 demonstrated comparable efficacy to Otezla® (apremilast) and Sotyktu® (deucravacitinib) in preclinical models for psoriasis treatment
+4 more records
Product overview1 text field

Kobiolabs is a microbiome therapeutics company developing drugs based on two integrated platforms: Smartiome® for AI-based multi-omics drug discovery using a microbiome library of 8,000+ strains, and Smartiome 2.0 incorporating digital-bio technology and biofoundry capabilities. The company pipeline spans multiple therapeutic areas including immunology (KBL697 for psoriasis, KBL693 for asthma), metabolism (KBLP-004 for obesity, KBL983), immuno-oncology (KBLP-005), CNS (KBLP-010 for ASD), and gastroenterology (KBLP-006 for IBD, KBL382/KBL385 for IBS-d). The proprietary mDDS technology enables microbe-based drug delivery for enhanced therapeutic efficacy.

Product and service11 records
1Smartiome®
CategoryDrug Discovery Platform
2Smartiome 2.0
CategoryDrug Discovery Platform
3mDDS (Microbe-Based Drug Delivery System)
CategoryDrug Delivery Technology
4KBL697
CategoryClinical-Stage Drug Candidate
5KBL693
CategoryClinical-Stage Drug Candidate
6KBLP-004
CategoryPreclinical Drug Candidate
7KBLP-005
CategoryPreclinical Drug Candidate
8KBLP-006
CategoryPreclinical Drug Candidate
9KBLP-010
CategoryClinical-Stage Drug Candidate
10KBL409
CategoryFunctional Strain Product
11KBL983
CategoryFunctional Strain Product
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

License-in agreement for three microbiome-based drug candidates (KC84, KBL382, KBL385) targeting intestinal diseases including IBS-d. Deal valued at up to 205.2 billion won ($136.8 million). Celltrion receives exclusive global rights for clinical development and commercialization across all intestinal disease indications. The agreement includes non-refundable upfront payment, milestones for clinical progress, regulatory approvals, and commercialization, plus royalties on net sales.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Seres is a US microbiome therapeutics company developing engineered consortia and single-strain LBPs for serious diseases. Both companies target similar indications (IBD, immuno-oncology) using live biotherapeutic approaches, making Seres the closest comparable in business model and pipeline scope.

TypeDirect peer
Description

Vedanta develops defined bacterial consortia as live biotherapeutics for immune-mediated diseases including IBD and infectious disease. Direct competitor in the consortium-based LBP space with comparable IND-stage pipeline assets.

34D pharma
TypeDirect peer
Description

4D pharma (now part of AbbVie) developed single-strain LBPs (e.g., Blautix for IBS) using a MicroRx discovery platform. Most directly comparable to Kobiolabs' IBS-d program and single-strain discovery approach; AbbVie acquisition validates category economics.

TypeDirect peer
Description

French clinical-stage microbiome therapeutics company developing standardized, high-richness donor-derived LBPs for oncology and gut diseases. Comparable in disease focus (IBD/GvHD) and global clinical trial execution.

TypeDirect peer
Description

Evelo develops oral microbiome-based therapies for inflammatory diseases and oncology. Similar platform approach using single-strain LBPs with IND-stage pipeline; competitive overlap in psoriasis and immuno-oncology indications.

TypeDirect peer
Description

Eligo develops engineered phage-based microbiome therapies — a next-generation approach parallel to Kobiolabs' mDDS. Both companies are pushing beyond traditional LBPs into engineered microbe delivery, with similar early-stage clinical positioning.

TypeBroad incumbent
Description

Celltrion is Kobiolabs' largest licensing partner and a major Korean biosimilars/biologics company. It is a broader incumbent in the same Korean biotech ecosystem that validates and commercializes Kobiolabs' candidates, making it both partner and ecosystem comparable.

8Second Genome
TypeEmerging player
Description

Second Genome applies microbiome science to drug discovery in inflammation, metabolic disease, and CNS disorders. Overlapping indications (IBD, metabolic) and comparable platform-discovery business model.

TypeEmerging player
Description

Assembly Bio develops microbiome-based therapies with pipeline overlap in inflammatory and gastrointestinal diseases. Comparable scale and clinical-stage positioning in the broader microbiome therapeutics field.

TypeBroad incumbent
Description

Major Korean biopharmaceutical CDMO with established CMC capabilities relevant to LBP manufacturing. Comparable as a Korean-listed biotech incumbent and potential future manufacturing partner given Kobiolabs' claim of in-house CMC capability for global LBP guidelines.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kobiolabs

Microbiome Therapeuticskobiolabs.com

KoBioLabs is a South Korean, KOSDAQ-listed clinical-stage biopharmaceutical company developing AI-driven, microbiome-based Live Biotherapeutic Products for immune, metabolic, neurological, and gastrointestinal diseases, monetizing its pipeline through out-licensing to global pharmaceutical partners and research collaborations.

What Kobiolabs does

KoBioLabs (고바이오랩) is a South Korea-based, KOSDAQ-listed (ticker 348150) clinical-stage biopharmaceutical company developing Live Biotherapeutic Products (LBPs) from microbiome science for immune, metabolic, neurological, and gastrointestinal diseases. The company operates two integrated discovery platforms — Smartiome®, an AI-based multi-omics analysis platform paired with a microbial strain library of over 8,000 isolates, and Smartiome® 2.0, which adds biofoundry and digital-bio capabilities — together with a proprietary Microbe-Based Drug Delivery System (mDDS) that uses engineered gut microbes to produce therapeutic substances in vivo. Its clinical pipeline spans KBL697 (psoriasis, Phase II complete), KBL693 (asthma, Phase I complete with US FDA IND pending), KBLP-004 (obesity consortium), KBLP-005 (immuno-oncology), KBLP-006 (IBD), KBLP-010 (autism spectrum disorder), KBL409 (chronic kidney disease), and KBL983 (Akkermansia muciniphila for obesity, US-patent protected).

The company's business model is a license-out and research collaboration model rather than direct product sales. Revenue is generated through upfront payments, development and regulatory milestones, and royalties on net sales from global pharmaceutical partners, exemplified by the March 2026 Celltrion license for three intestinal-disease candidates valued at up to 205.2 billion KRW ($136.8 million) — the largest agreement in company history and equal to 417% of 2025 consolidated equity. Additional monetization channels include research collaborations with partners such as Celltrion, a regional China out-license to SPH Sine for KBL697 (2021), and a 2022 joint venture with Emart (Wibiome / 위바이오옴) for health functional foods. Customer segments are exclusively enterprise biopharmaceutical and corporate partners, served via major international biotech conferences (BIO USA, JP Morgan Healthcare Conference, IHMC) rather than direct sales infrastructure.

Kobiolabs firmographics

Firmographics
Name
Kobiolabs
Legal name
(주)고바이오랩
Website
https://kobiolabs.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
KoBioLabs is a South Korean, KOSDAQ-listed clinical-stage biopharmaceutical company developing AI-driven, microbiome-based Live Biotherapeutic Products for immune, metabolic, neurological, and gastrointestinal diseases, monetizing its pipeline through out-licensing to global pharmaceutical partners and research collaborations.
Ownership category
akta.pro rank

Kobiolabs industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Microbiome therapeutics
  • Live biotherapeutic products
  • Drug discovery platform
  • Multi-omics analysis
  • Synthetic biology

Where Kobiolabs is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Kobiolabs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: License-out deals with global pharmaceutical companies for drug candidates, including upfront payments, milestone payments tied to clinical progress, regulatory approvals, and commercialization, plus royalties on net sales.
  2. Research Collaboration: Joint research collaborations with partners like Celltrion for co-development of microbiome-based therapeutics, with shared development costs and potential future revenue sharing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Kobiolabs product offering

Product offering

Core offering

KoBioLabs is a South Korean biopharmaceutical company developing microbiome-based therapeutics (Live Biotherapeutic Products) using its proprietary Smartiome® AI-based multi-omics platform combined with a microbiome library of 8,000+ strains. The company discovers, develops, and out-licenses drug candidates targeting immune, metabolic, neurological, and gastrointestinal diseases to global pharmaceutical partners. Its pipeline includes candidates for psoriasis (KBL697), asthma (KBL693), obesity (KBLP-004, KBL983), inflammatory bowel disease (KBLP-006), autism spectrum disorder (KBLP-010), and chronic kidney disease (KBL409).

Product overview

Kobiolabs is a microbiome therapeutics company developing drugs based on two integrated platforms: Smartiome® for AI-based multi-omics drug discovery using a microbiome library of 8,000+ strains, and Smartiome 2.0 incorporating digital-bio technology and biofoundry capabilities. The company pipeline spans multiple therapeutic areas including immunology (KBL697 for psoriasis, KBL693 for asthma), metabolism (KBLP-004 for obesity, KBL983), immuno-oncology (KBLP-005), CNS (KBLP-010 for ASD), and gastroenterology (KBLP-006 for IBD, KBL382/KBL385 for IBS-d). The proprietary mDDS technology enables microbe-based drug delivery for enhanced therapeutic efficacy.

Differentiator

Problem solved

Functional benefit

Brands

  • Smartiome: AI기반 마이크로바이옴 다중오믹스(multi-omics) 분석 기술 및 미생물 라이브러리를 활용한 혁신 신약 개발 플랫폼 기술.
  • Smartiome 2.0
  • mDDS (Microbe-Based Drug Delivery System)

Products and services

  • Smartiome®
  • Smartiome 2.0
  • mDDS (Microbe-Based Drug Delivery System)
  • KBL697
  • KBL693
  • KBLP-004
  • KBLP-005
  • KBLP-006
  • KBLP-010
  • KBL409
  • KBL983

Quantifiable outcome

  • KBL697 demonstrated comparable efficacy to Otezla® (apremilast) and Sotyktu® (deucravacitinib) in preclinical models for psoriasis treatment
  • +4 more outcomes

Companies that use Kobiolabs

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Kobiolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Kobiolabs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CelltrionflagshipStrategic or Co-development Partner · 25 March 2026License-in agreement for three microbiome-based drug candidates (KC84, KBL382, KBL385) targeting intestinal diseases including IBS-d. Deal valued at up to 205.2 billion won ($136.8 million). Celltrion receives exclusive global rights for clinical development and commercialization across all intestinal disease indications. The agreement includes non-refundable upfront payment, milestones for clinical progress, regulatory approvals, and commercialization, plus royalties on net sales.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Kobiolabs competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Seres is a US microbiome therapeutics company developing engineered consortia and single-strain LBPs for serious diseases. Both companies target similar indications (IBD, immuno-oncology) using live biotherapeutic approaches, making Seres the closest comparable in business model and pipeline scope.
  • Vedanta Biosciences: Vedanta develops defined bacterial consortia as live biotherapeutics for immune-mediated diseases including IBD and infectious disease. Direct competitor in the consortium-based LBP space with comparable IND-stage pipeline assets.
  • 4D pharma: 4D pharma (now part of AbbVie) developed single-strain LBPs (e.g., Blautix for IBS) using a MicroRx discovery platform. Most directly comparable to Kobiolabs' IBS-d program and single-strain discovery approach; AbbVie acquisition validates category economics.
  • MaaT Pharma: French clinical-stage microbiome therapeutics company developing standardized, high-richness donor-derived LBPs for oncology and gut diseases. Comparable in disease focus (IBD/GvHD) and global clinical trial execution.
  • Evelo Biosciences: Evelo develops oral microbiome-based therapies for inflammatory diseases and oncology. Similar platform approach using single-strain LBPs with IND-stage pipeline; competitive overlap in psoriasis and immuno-oncology indications.
  • Eligo Bioscience: Eligo develops engineered phage-based microbiome therapies — a next-generation approach parallel to Kobiolabs' mDDS. Both companies are pushing beyond traditional LBPs into engineered microbe delivery, with similar early-stage clinical positioning.

Broad incumbents

  • Celltrion: Celltrion is Kobiolabs' largest licensing partner and a major Korean biosimilars/biologics company. It is a broader incumbent in the same Korean biotech ecosystem that validates and commercializes Kobiolabs' candidates, making it both partner and ecosystem comparable.
  • Samsung Biologics: Major Korean biopharmaceutical CDMO with established CMC capabilities relevant to LBP manufacturing. Comparable as a Korean-listed biotech incumbent and potential future manufacturing partner given Kobiolabs' claim of in-house CMC capability for global LBP guidelines.

Emerging players

  • Second Genome: Second Genome applies microbiome science to drug discovery in inflammation, metabolic disease, and CNS disorders. Overlapping indications (IBD, metabolic) and comparable platform-discovery business model.
  • Assembly Biosciences: Assembly Bio develops microbiome-based therapies with pipeline overlap in inflammatory and gastrointestinal diseases. Comparable scale and clinical-stage positioning in the broader microbiome therapeutics field.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Kobiolabs social profiles

Digital presence

Kobiolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kobiolabs leadership team

Management profile

Number of profiles

Profiles6 records

Kobiolabs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kobiolabs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kobiolabs M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kobiolabs

What does Kobiolabs do?

KoBioLabs is a South Korean biopharmaceutical company developing microbiome-based therapeutics (Live Biotherapeutic Products) using its proprietary Smartiome® AI-based multi-omics platform combined with a microbiome library of 8,000+ strains. The company discovers, develops, and out-licenses drug candidates targeting immune, metabolic, neurological, and gastrointestinal diseases to global pharmaceutical partners. Its pipeline includes candidates for psoriasis (KBL697), asthma (KBL693), obesity (KBLP-004, KBL983), inflammatory bowel disease (KBLP-006), autism spectrum disorder (KBLP-010), and chronic kidney disease (KBL409).

Is Kobiolabs a public or private company?

Kobiolabs is a public company. It is classified as public and is currently operating.

When was Kobiolabs founded?

Kobiolabs was founded in 2014. It employs 11 to 50 people.

Where is Kobiolabs based?

Kobiolabs is headquartered in Seongnam, South Korea, in the Asia region.

How does Kobiolabs make money?

Two revenue lines are on record. Technology Licensing is the primary driver. The others are research Collaboration.

Who are Kobiolabs's main competitors?

Direct peers on record are Seres Therapeutics, Vedanta Biosciences, 4D pharma, MaaT Pharma, Evelo Biosciences and Eligo Bioscience. Broad incumbents are Celltrion and Samsung Biologics. Emerging players are Second Genome and Assembly Biosciences.

Does Kobiolabs have an API?

No public API is recorded for Kobiolabs.

What industry is Kobiolabs in?

Kobiolabs's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals